12th July 2021
Bemcentinib, an oral AXL kinase inhibitor, results in lower mortality compared to standard of care (steroids with or without remdesivir) in hospitalised patients with COVID-19
Selective AXL inhibitors
Footer
Selective AXL inhibitors
12th July 2021
Bemcentinib, an oral AXL kinase inhibitor, results in lower mortality compared to standard of care (steroids with or without remdesivir) in hospitalised patients with COVID-19